News

TIF is delighted to receive the following exciting news on the launch of the Thalassemia Patients Advocacy Group  during the “Seminar on the Policy Interventions for the Evolving Needs of Thalassemics in India” on 16th Sep 2017 at New Delhi. At the presence of officials from the Ministry of Health, the Indian Red ...

EMA Survey on the safety of medicines and on the reporting of adverse drug reactions. Survey available at: https://ec.europa.eu/…/EMA-survey-on-reporting-adverse-drug… Tags: #patientsafety #SideEffects #pharmacovigilance.   TIF’s position: The Thalassaemia International Federation (TIF) has focused attention for some time now and continues to do so, on the need for more strengthened and coordinated actions towards ...

The life and times of the incredible Shobha Tuli feature in the newly released book “Weaving Dreams Into Reality… Inspiring Women” by Dr Gagandeep Kaur Gulati. The book was launched on 27 August 2017. Undoubtedly, Mrs Tuli’s journey should be shared across. Her life commitment to the global thalassaemia family is ...

The Thalassaemia International Federation (TIF) is delighted to announce the organisation of the 14th International Conference on Thalassaemia & Haemoglobinopathies & 16th TIF International Conference for Patients & Parents.

Coal India Ltd. under their CSR activity in coordination with the Ministry of Health and Family Welfare, Govt. of India has approved an HSCT project for the cure of thalassemia patients. They would like to help 200 patients in a year. Thalassemics India has been given an opportunity to coordinate this ...

Patients’ stories of health care harm touch people’s hearts. The stories of the experiences of how patients and families can and do turn tragedy into compassion and motivation for change inspire people and help to raise awareness of the need to improve patient safety and health care quality.

Congratulations to India for moving forward! Two major advancements announced: The release of “Guidelines on “Prevention and Control of Haemoglobinopathies in India” by the Ministry of Health and Family Welfare, Govt. of India. We note that 2 out of the 26 contributors are from Thalassemics India.

Important Note: The latest Clinical Trial updates can be found in the link below.   April 2017 update Luspatercept (ACE-536): A novel agent that increases haemoglobin by promoting erythropoiesis (differentiation and maturation of late-stage erythrocyte precursors). Phase 2 data in adults with β-thalassaemia shows sustained increase in haemoglobin levels with ...